BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Knight JR, Locke GR 3rd, Zinsmeister AR, Schleck CD, Talley NJ. Family history of mental illness or alcohol abuse and the irritable bowel syndrome. J Psychosom Res 2015;78:237-41. [PMID: 25582802 DOI: 10.1016/j.jpsychores.2014.11.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Rahal H, Videlock EJ, Icenhour A, Shih W, Naliboff B, Gupta A, Mayer EA, Chang L. Importance of trauma-related fear in patients with irritable bowel syndrome and early adverse life events. Neurogastroenterol Motil 2020;32:e13896. [PMID: 32558017 DOI: 10.1111/nmo.13896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Namba MD, Leyrer-Jackson JM, Nagy EK, Olive MF, Neisewander JL. Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities. Front Neurosci 2021;15:650785. [PMID: 33935636 DOI: 10.3389/fnins.2021.650785] [Reference Citation Analysis]
3 Gendi R, Jahan N. Pharmacological and Non-pharmacological Treatments of Irritable Bowel Syndrome and Their Impact on the Quality of Life: A Literature Review. Cureus 2020;12:e9324. [PMID: 32850202 DOI: 10.7759/cureus.9324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yeh TC, Bai YM, Tsai SJ, Chen TJ, Liang CS, Chen MH. Risks of Major Mental Disorders and Irritable Bowel Syndrome among the Offspring of Parents with Irritable Bowel Syndrome: A Nationwide Study. Int J Environ Res Public Health 2021;18:4679. [PMID: 33924787 DOI: 10.3390/ijerph18094679] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Park SH, Videlock EJ, Shih W, Presson AP, Mayer EA, Chang L. Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity. Neurogastroenterol Motil 2016;28:1252-60. [PMID: 27061107 DOI: 10.1111/nmo.12826] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
6 Foxx-Orenstein AE. New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol 2016;9:354-75. [PMID: 27134665 DOI: 10.1177/1756283X16633050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
7 Low EXS, Mandhari MNKA, Herndon CC, Loo EXL, Tham EH, Siah KTH. Parental, Perinatal, and Childhood Risk Factors for Development of Irritable Bowel Syndrome: A Systematic Review. J Neurogastroenterol Motil 2020;26:437-46. [PMID: 32989183 DOI: 10.5056/jnm20109] [Reference Citation Analysis]
8 Fodor AA, Pimentel M, Chey WD, Lembo A, Golden PL, Israel RJ, Carroll IM. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes 2019;10:22-33. [PMID: 29708822 DOI: 10.1080/19490976.2018.1460013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
9 Li Y, Zhang W, Ma J, Chen M, Lin B, Yang X, Li F, Tang X, Wang F. Study on the regulation of brain–gut peptide by Shenling Baizhu San in functional diarrhea rats. Journal of Traditional Chinese Medical Sciences 2018;5:283-90. [DOI: 10.1016/j.jtcms.2018.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]